Core Insights - Scienture Holdings, Inc. is participating in the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, focusing on drug discovery and development [1][3] - Dr. Narasimhan Mani will present on technology-driven product innovations and market strategies in the specialty pharmaceutical industry [2][5] - The SSX conference aims to facilitate knowledge sharing among scientists and industry experts in the field of drug discovery [3] Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing novel specialty pharmaceutical products to meet unmet market needs [5] - The company is involved in various therapeutic areas and markets, including government organizations, hospitals, and independent pharmacies [5] Conference Details - The SSX 2025 Conference will take place from January 23-25, 2025, at BITS Pilani, Hyderabad Campus [1] - The event will feature expert panels, presentations, and networking opportunities with industry veterans [7]

Core Insights - Scienture Holdings, Inc. is participating in the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, focusing on drug discovery and development [1][3] - Dr. Narasimhan Mani will present on technology-driven product innovations and market strategies to enhance patient access to novel therapies [2][5] - The SSX conference aims to provide a platform for knowledge exchange among scientists in the DMPK/ADMET fields, showcasing trends in the global pharmaceutical industry [3][7] Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on delivering novel specialty pharmaceutical products to meet unmet market needs [5] - The company is involved in various therapeutic areas and market segments, including government organizations, hospitals, and independent pharmacies [5] Conference Details - The SSX 2025 Conference will take place from January 23-25, 2025, at BITS Pilani, Hyderabad Campus, featuring expert panels and presentations [1][4] - The event has seen a steady increase in participation from industry experts, scientists, and students over the years [3]

Company Overview - Scienture Holdings, Inc. is a specialty pharmaceutical company with a novel pipeline of brand products, focusing on providing enhanced value to patients, physicians, and caregivers through specialty products that address unmet market needs [6] - The company operates through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC, which cater to various therapeutic areas and market segments [6] Event Participation - Scienture Holdings will participate in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ [1] - The management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities [2] Conference Details - The Microcap Conference is the largest independent microcap event in the U.S., providing a platform for companies to showcase their value propositions through presentations and networking opportunities [3] - The 2025 event will feature keynote speakers, expert panels, and entertainment, including a fireside chat with industry figures and insights on investing and market trends [4]

Financial Performance - Revenues for the three months ended September 30, 2024, were $64,861, compared to $83,560 for the same period in 2023, representing a decrease of approximately 22.4%[6] - Gross profit for the nine months ended September 30, 2024, was $39,592, down from $162,990 in 2023, indicating a decline of about 75.8%[6] - The net loss from continuing operations for the three months ended September 30, 2024, was $(3,183,601), compared to $(88,136) in 2023, marking a significant increase in losses[6] - The company reported a net loss per common share from continuing operations of $(1.34) for the three months ended September 30, 2024, compared to $(0.11) in the same period of 2023[6] - The company reported a net loss of $(3,183,601) for the quarter ending September 30, 2024[7] - The company reported a net loss from continuing operations of $11,441,764 for the nine months ended September 30, 2024, compared to a loss of $3,429,112 for the same period in 2023, indicating a significant increase in losses[8] - The net income (loss) on discontinued operations for the three months ended September 30, 2024, was $27,670,294, compared to a loss of $2,748,833 in the same period of 2023[40] - The company reported a loss on the disposition of business amounting to $2,083,742, included in income from discontinued operations, net of tax[37] Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $3,501,674, compared to $801,270 in the same period of 2023, reflecting an increase of approximately 337.5%[6] - Total operating expenses rose by $7,783,789 to $10,489,633, a 355% increase compared to the same period in 2023[85] - Research and development expenses for the three months ended September 30, 2024, were $1,253,983, with no comparable expenses reported in the same period of 2023[6] - Research and development expenses were $1,253,983 for the nine months ended September 30, 2024, compared to $0 in the same period of 2023, due to costs associated with the Scienture merger[85] Cash Flow and Assets - Cash at the end of the period was $579,103 as of September 30, 2024, compared to $34,031 at the end of the previous period[8] - The company has $4,505,797 in other receivables as of September 30, 2024, primarily consisting of short-term advances to Wellgistics Health, Inc.[21] - Cash provided by investing activities for the nine months ended September 30, 2024, was $27,552,791, compared to $74,283 for the same period in 2023[81] - Current assets (excluding cash) rose to $6,676,813 as of September 30, 2024, compared to $2,752,749 at the end of 2023, marking an increase of 143%[77] - Current liabilities decreased to $5,413,438 as of September 30, 2024, from $11,556,355 at the end of 2023, representing a reduction of 53%[77] Equity and Stock Transactions - The company executed a 1:15 reverse stock split on June 21, 2023, to comply with Nasdaq Listing Rule 5550(a)(2)[18] - The company issued common stock for services totaling $4,450,914 during the reporting period[7] - The Company issued 291,536 shares of common stock and 6,826,753 shares of Series X Preferred Stock as part of the Scienture Merger Agreement, with a total fair value of $78,646,184[56] - The Company authorized the issuance of up to 9,211,246 shares of Series X Preferred Stock, convertible into common stock[53] Acquisitions and Mergers - The company completed the acquisition of Superlatus on July 31, 2023, with a total value of $225,000,169, which included 136,441 shares of common stock and 306,855 shares of Series B Preferred Stock[10] - The company entered into a merger agreement with Scienture on July 25, 2024, resulting in the issuance of 291,536 shares of common stock and 6,826,753 shares of Series X Non-Voting Convertible Preferred Stock[11] - The Company acquired Scienture, Inc. for a total purchase consideration of $78,646,184, which included 291,536 shares of common stock and 6,826,753 shares of Series X Preferred Stock[27][28] Strategic Changes - The company anticipates dissolving Bonum Health, LLC, which was formed to hold telehealth assets, indicating a strategic shift in focus[9] - The company plans to commercialize innovative and branded pharmaceutical products in the US market through its subsidiary Scienture, targeting unmet medical needs[9] - The company plans to raise additional funding through equity sales and debt to support ongoing operations and potential acquisitions[79] Legal and Compliance - The company won a legal case against Studebaker Defense Group, LLC, with a court order for $550,000, but no payments have been received as of the filing date[63] - The company has a termination fee liability of $1,285,000 related to the agreement with Kesin Pharma Corporation, which remains outstanding as of September 30, 2024[65] Debt and Financing - The Company entered into a Loan and Security Agreement for $2,000,000 with NVK Finance, LLC, with an interest rate of 15.50% as of September 30, 2024[46] - A convertible note of $360,000 was issued in August 2024, with net proceeds of $314,000 and a monthly amortization payment of $7,200 starting six months after issuance[47] - The Company has accrued interest on its loans totaling $18,432 as of December 31, 2023[51]